According to recent recommendations, human plasma-derived or recombinant FVIII concentrates can be used in acquired hemophilia for the treatment of minor bleeding manifestations and acute bleeding episodes when the inhibitor titer is low (≤ 5BU) [2], and no bypassing agent is immediately available, as was the case with our patient. Here, F8 is linked to hemophilia.